Dongyang Guangyao said its insulin glargine injection, approved by the U.S. FDA
in April, began U.S. commercial shipments in July with an initial batch of 1.152
mln units. The company has locked more than 18 mln units in overseas orders; the
product is the first Chinese insulin to enter the U.S. market.
